To cite this paper use one of the standards below:
Colon cancer is a major contributor to cancer mortality globally, with few treatment alternatives for advanced cases. Targeting both cell proliferation and apoptosis pathways has become a promising approach in anticancer therapy. Palbociclib, a CDK4/6 inhibitor, has shown efficacy in halting cancer cell proliferation by disrupting cell cycle progression. Meanwhile, the VIPASY peptide from cowpea bean’s β-vignin protein has shown the potential to induce cell death in HCT-116 colon cancer cells by modulating the apoptotic pathway. Therefore, in this study, we investigated the effects of VIPASY, palbociclib, and their combination on HCT-116 colon cancer cells, focusing on key molecular markers associated with cell survival, cell cycle regulation, and apoptosis. Cell viability of colon cancer cells (HCT-116) was assessed after 24h treatment with VIPASY peptide (200 µM), palbociclib (PAL) (280 µM), and their combination/co-treatment (VIPASY 200 µM + PAL 280 µM). The relative protein expression of apoptotic markers (TNF-R1, caspase-4, caspase-8) and survival/cell cycle-related markers (SIRT1, thioredoxin, Cdc2) on HCT-116 cells treated for 24 h with VIPASY peptide, palbociclib (PAL) and their co-treatment (VIPASY + PAL) was evaluated. HCT-116 cell viability was affected by VIPASY (64%) and palbociclib (72%), however, co-treatment of VIPASY+PAL had a more significant effect on reducing the viability (45%). TNF-R1 was significantly downregulated with VIPASY-PAL treatment (-70%) compared to VIPASY treatment (-18%), and caspase-8 was upregulated with VIPASY-PAL treatment (+35%), suggesting that the VIPASY-PAL treatment might induce apoptosis by the extrinsic pathway. Thioredoxin, a key antioxidant protein that is often overexpressed in cancer cells, was downregulated with VIPASY (-38%), palbociclib (-23%), and even more with VIPASY-PAL treatment (-57%). Caspase-4 and SIRT1 were not affected by VIPASY-PAL treatment (p>0.05). And Cdc2 expression, a key player in cell cycle regulation, was reduced by 90% following VIPASY-PAL treatment. Our work shows the potential of VIPASY-palbociclib co-treatment on HCT-116 cells.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper